` ETON (Eton Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ETON
vs
S&P 500

Over the past 12 months, ETON has significantly outperformed S&P 500, delivering a return of 243% compared to the S&P 500's 2% drop.

Stocks Performance
ETON vs S&P 500

Loading

Performance Gap
ETON vs S&P 500

Loading
ETON
S&P 500
Difference

Performance By Year
ETON vs S&P 500

Loading
ETON
S&P 500
Add Stock

Competitors Performance
Eton Pharmaceuticals Inc vs Peers

S&P 500
ETON
LLY
JNJ
NOVO B
ROG
Add Stock

Eton Pharmaceuticals Inc
Glance View

Market Cap
316m USD
Industry
Pharmaceuticals

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.

ETON Intrinsic Value
21.23 USD
Undervaluation 44%
Intrinsic Value
Price
Back to Top